Associated tags: Messenger, Epigenome, Cell, Gene expression, Ageing, Pharmaceutical industry, Dermatology, Vaccine, ERA, Research, Epigenetics, Disease, Skin, Ophthalmology, RNA transfection, Osteoarthritis
Locations: MONACO, CALIFORNIA, CHICAGO
Retrieved on:
Wednesday, January 3, 2024
Particle size,
Messenger,
Fibroblast,
PEG,
Tissue,
Macrophage,
Ionization,
Keratinocyte,
Lipid,
Blood,
Endothelium,
Transfection,
Cell,
Safety,
Medicine,
Skin,
Vaccine The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.
Key Points:
- The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.
- Since the platform can utilize PEG-free stabilizing components, the delivery system minimizes or eliminates immunogenicity associated with PEG lipids currently used in LNPs.
- "It is designed to enable the delivery of therapies to treat incurable diseases by targeting cells that medicine cannot currently reach.
- Turn Bio's first drug candidates are focused on treating the skin by targeting specific cells including fibroblasts, endothelial cells and keratinocytes.
Retrieved on:
Wednesday, January 3, 2024
Particle size,
Messenger,
Fibroblast,
PEG,
Tissue,
Macrophage,
Ionization,
Keratinocyte,
Lipid,
Blood,
Endothelium,
Transfection,
Cell,
Safety,
Medicine,
Skin,
Vaccine The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.
Key Points:
- The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.
- Since the platform can utilize PEG-free stabilizing components, the delivery system minimizes or eliminates immunogenicity associated with PEG lipids currently used in LNPs.
- "It is designed to enable the delivery of therapies to treat incurable diseases by targeting cells that medicine cannot currently reach.
- Turn Bio's first drug candidates are focused on treating the skin by targeting specific cells including fibroblasts, endothelial cells and keratinocytes.
Retrieved on:
Tuesday, November 7, 2023
Therapy,
Spleen,
ASDS,
Liver,
Skin,
Research,
Society,
Fibroblast,
Transfection,
Tissue,
Lipid,
Messenger,
Safety,
Gene expression,
Vaccine,
Veterinary medicine,
Dermatology The company used its eTurna lipid nanoparticle delivery platform to precisely reach in vivo dermal fibroblasts with an mRNA formulation.
Key Points:
- The company used its eTurna lipid nanoparticle delivery platform to precisely reach in vivo dermal fibroblasts with an mRNA formulation.
- The eTurna-delivered formulation remained localized in the injection site and did not distribute to other organs.
- Turn Bio's most recent research was shared at the American Society for Dermatologic Surgery Annual Meeting held Nov. 2-5 in Chicago.
- "It shows promise to significantly expand the therapies dermatologists can provide – and dramatically improve the quality of our patients' lives."
Retrieved on:
Tuesday, November 7, 2023
Therapy,
Spleen,
ASDS,
Liver,
Skin,
Research,
Society,
Fibroblast,
Biotechnology,
Transfection,
Tissue,
Lipid,
Messenger,
Safety,
Gene expression,
Vaccine,
Veterinary medicine,
Dermatology The company used its eTurna lipid nanoparticle delivery platform to precisely reach in vivo dermal fibroblasts with an mRNA formulation.
Key Points:
- The company used its eTurna lipid nanoparticle delivery platform to precisely reach in vivo dermal fibroblasts with an mRNA formulation.
- The eTurna-delivered formulation remained localized in the injection site and did not distribute to other organs.
- Turn Bio's most recent research was shared at the American Society for Dermatologic Surgery Annual Meeting held Nov. 2-5 in Chicago.
- "It shows promise to significantly expand the therapies dermatologists can provide – and dramatically improve the quality of our patients' lives."
Retrieved on:
Wednesday, October 25, 2023
The meeting focused on the path forward for TRN-001, which would be the first treatment to repair damaged skin at the cellular level, improving its integrity and reducing inflammation and cell senescence.
Key Points:
- The meeting focused on the path forward for TRN-001, which would be the first treatment to repair damaged skin at the cellular level, improving its integrity and reducing inflammation and cell senescence.
- The results of the INTERACT meeting mean that Turn Bio is well positioned to be the first company to take a cell rejuvenation therapy to clinical trials.
- "We were gratified at the strong alignment between Turn Bio's approach to developing TRN-001 and the comments of FDA reviewers," said Anja Krammer, CEO of Turn Bio.
- TRN-001 was developed using Turn Bio's proprietary ERA™ technology, an mRNA-based platform designed to restore youthful function to cells.
Tissue,
Sebastiano,
RNA,
Cell,
Messenger,
ERA,
Patient,
Extracellular matrix,
King,
ECM,
LNP,
Congress,
King's College,
Conference,
Skin,
Safety,
Vaccine Sebastiano was invited to be a key faculty member during the SEASON Aesthetic Conference 2023, at King's College in London on June 9-11.
Key Points:
- Sebastiano was invited to be a key faculty member during the SEASON Aesthetic Conference 2023, at King's College in London on June 9-11.
- A pioneer in epigenetic reprogramming, he discussed the efficacy and safety of this therapy.
- "Epigenetic reprogramming promises to be a powerful tool that may transform how patients are treated," Sebastiano said.
- Turn Bio previously presented data at the SEASON Aesthetic Conference in Washington D.C. in April.
Society,
All Ages,
Ageing,
Sebastiano,
Research,
Messenger,
Notifiable disease,
Longevity,
Woman,
Skin,
JST,
Vaccine Sebastiano, a pioneer in epigenetic reprogramming, will be the only speaker at the 23rd Annual Meeting of the Japanese Society of Anti-Aging Medicine (JAAM) representing a non-Japanese company.
Key Points:
- Sebastiano, a pioneer in epigenetic reprogramming, will be the only speaker at the 23rd Annual Meeting of the Japanese Society of Anti-Aging Medicine (JAAM) representing a non-Japanese company.
- Sebastiano and his team have used Turn Bio's ERA™ technology to reprogram several cell types, including skin and immune cells.
- "Our success in the lab shows that epigenetic reprogramming offers great promise for overcoming these currently incurable conditions."
- The theme for this JAAM meeting is "Anti-Aging for Men and Women of All Ages – From Womb to Tomb."
Matrix metalloproteinase,
Paul Khavari,
ISID,
Matrix metalloproteinase inhibitor,
Regeneration,
Research,
Cell,
Messenger,
ERA,
Cellular senescence,
Oxidative stress,
International Society for Infectious Diseases,
Extracellular matrix,
ECM,
Wound healing,
Shinjuku,
Epigenetics,
Shinjuku NS Building,
Skin,
JST,
Medical device,
Dermatology,
Ageing MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin.
Key Points:
- MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin.
- Turn Bio's late-breaking abstract was accepted for presentation during the prestigious International Societies for Investigative Dermatology (ISID) Meeting, in Tokyo, Japan.
- Data will show that transient reprogramming with Turn Bio's Epigenetic Reprogramming of Aging (ERA™) technology rejuvenates cells within the extracellular matrix (ECM), resulting in comprehensive changes related to improved skin quality and structure.
- Turn Bio data will be presented by Dr. Edward Hsia, vice president of Dermatology at Turn Bio.
MOUNTAIN VIEW, Calif., May 9, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, today announced that Chief Executive Officer, Anja Krammer, will present an updated corporate overview at the JMP Securities Life Sciences Conference in New York City being held May 15th-16th, 2023 in New York City.
Key Points:
- MOUNTAIN VIEW, Calif., May 9, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, today announced that Chief Executive Officer, Anja Krammer, will present an updated corporate overview at the JMP Securities Life Sciences Conference in New York City being held May 15th-16th, 2023 in New York City.
- The presentation will take place on Monday, May 15, 2023, at 1:30 p.m. Eastern Time.
Maintenance,
Bio,
Stem cell,
Biotechnology,
Research,
Cosmetic,
Messenger,
ERA,
Patient,
Extracellular matrix,
Faculty,
ECM,
Epigenetics,
George Washington University,
Conference,
Skin,
Medical device,
Dermatology,
Ageing MOUNTAIN VIEW, Calif., May 1, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, shared data demonstrating the significant potential of using epigenetic reprogramming to rejuvenate skin before an international audience of regenerative aesthetics experts.
Key Points:
- MOUNTAIN VIEW, Calif., May 1, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, shared data demonstrating the significant potential of using epigenetic reprogramming to rejuvenate skin before an international audience of regenerative aesthetics experts.
- The data discussed at SEASON Aesthetic Conference showed that Turn Bio's Epigenetic Reprogramming of Aging (ERA™) technology reprograms cells within the extracellular matrix (ECM), resulting in a broad panel of changes related to improved skin quality and structure.
- Research demonstrates that Turn Bio's cellular data in-vitro has translated to the tissue level ex-vivo.
- Dr. Hsia, who has worked in biotechnology for nearly 20 years, was gratified by the experience of presenting to SEASON attendees.
